NCT01820364View on ClinicalTrials.gov

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Melanoma
Interventions
DRUG

LGX818

BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.

Trial Locations (6)

3002

Novartis Investigative Site, East Melbourne

8091

Novartis Investigative Site, Zurich

37203

Sarah Cannon Research Institute Onc Dept, Nashville

69120

Novartis Investigative Site, Heidelberg

T6G 1Z2

Novartis Investigative Site, Edmonton

08035

Novartis Investigative Site, Barcelona

Sponsors

Lead Sponsor

Array BioPharma
All Listed Sponsors
lead

Array BioPharma

INDUSTRY